


NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Remimazolam. [Updated 2022 Mar 21]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Remimazolam

Revised: March 21, 2022.

CASRN: 308242-62-8



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of remimazolam during breastfeeding. Because it is very short acting, it is recommended that nursing mothers pump and discard breast milk for 5 hours after a dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Intravenous Sedation) Dexmedetomidine, Etomidate, Methohexital, Midazolam, Propofol

Substance Identification

Substance Name

Remimazolam

CAS Registry Number

308242-62-8

Drug Class

Breast Feeding

Lactation

Hypnotics and Sedatives

Benzodiazepines

Anesthetics, Intravenous